The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Prion Disease Drug Market Research Report 2024

Global Prion Disease Drug Market Research Report 2024

Publishing Date : Sep, 2023

License Type :
 

Report Code : 1723859

No of Pages : 94

Ask Your Query
Synopsis
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of rare and progressive neurological disorders caused by abnormal proteins called prions. Currently, there is no known cure for prion diseases, and treatment options are limited. However, there are ongoing research efforts and clinical trials aimed at developing drugs to treat or slow down the progression of these diseases.
Global Prion Disease Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prion Disease Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Prion Disease Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis AG
Merck KGaA
Aurobindo Pharma
AstraZeneca
Abbott
Ionis Pharmaceuticals
Lannett
Astellas Pharma Inc.
Sawai Pharmaceutical
Elite Pharmaceuticals, Inc.
Teva Pharmaceuticals
Bristol Myers Squibb
Segment by Type
Antidepressant
Antipsychotic Agents
Others
Segment by Application
Hospital
Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Prion Disease Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prion Disease Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antidepressant
1.2.3 Antipsychotic Agents
1.2.4 Others
1.3 Market by Application
1.3.1 Global Prion Disease Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prion Disease Drug Market Perspective (2018-2029)
2.2 Prion Disease Drug Growth Trends by Region
2.2.1 Global Prion Disease Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Prion Disease Drug Historic Market Size by Region (2018-2023)
2.2.3 Prion Disease Drug Forecasted Market Size by Region (2024-2029)
2.3 Prion Disease Drug Market Dynamics
2.3.1 Prion Disease Drug Industry Trends
2.3.2 Prion Disease Drug Market Drivers
2.3.3 Prion Disease Drug Market Challenges
2.3.4 Prion Disease Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prion Disease Drug Players by Revenue
3.1.1 Global Top Prion Disease Drug Players by Revenue (2018-2023)
3.1.2 Global Prion Disease Drug Revenue Market Share by Players (2018-2023)
3.2 Global Prion Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prion Disease Drug Revenue
3.4 Global Prion Disease Drug Market Concentration Ratio
3.4.1 Global Prion Disease Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prion Disease Drug Revenue in 2022
3.5 Prion Disease Drug Key Players Head office and Area Served
3.6 Key Players Prion Disease Drug Product Solution and Service
3.7 Date of Enter into Prion Disease Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prion Disease Drug Breakdown Data by Type
4.1 Global Prion Disease Drug Historic Market Size by Type (2018-2023)
4.2 Global Prion Disease Drug Forecasted Market Size by Type (2024-2029)
5 Prion Disease Drug Breakdown Data by Application
5.1 Global Prion Disease Drug Historic Market Size by Application (2018-2023)
5.2 Global Prion Disease Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Prion Disease Drug Market Size (2018-2029)
6.2 North America Prion Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Prion Disease Drug Market Size by Country (2018-2023)
6.4 North America Prion Disease Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prion Disease Drug Market Size (2018-2029)
7.2 Europe Prion Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Prion Disease Drug Market Size by Country (2018-2023)
7.4 Europe Prion Disease Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prion Disease Drug Market Size (2018-2029)
8.2 Asia-Pacific Prion Disease Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Prion Disease Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Prion Disease Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prion Disease Drug Market Size (2018-2029)
9.2 Latin America Prion Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Prion Disease Drug Market Size by Country (2018-2023)
9.4 Latin America Prion Disease Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prion Disease Drug Market Size (2018-2029)
10.2 Middle East & Africa Prion Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Prion Disease Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Prion Disease Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Prion Disease Drug Introduction
11.1.4 Novartis AG Revenue in Prion Disease Drug Business (2018-2023)
11.1.5 Novartis AG Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Detail
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Prion Disease Drug Introduction
11.2.4 Merck KGaA Revenue in Prion Disease Drug Business (2018-2023)
11.2.5 Merck KGaA Recent Development
11.3 Aurobindo Pharma
11.3.1 Aurobindo Pharma Company Detail
11.3.2 Aurobindo Pharma Business Overview
11.3.3 Aurobindo Pharma Prion Disease Drug Introduction
11.3.4 Aurobindo Pharma Revenue in Prion Disease Drug Business (2018-2023)
11.3.5 Aurobindo Pharma Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Prion Disease Drug Introduction
11.4.4 AstraZeneca Revenue in Prion Disease Drug Business (2018-2023)
11.4.5 AstraZeneca Recent Development
11.5 Abbott
11.5.1 Abbott Company Detail
11.5.2 Abbott Business Overview
11.5.3 Abbott Prion Disease Drug Introduction
11.5.4 Abbott Revenue in Prion Disease Drug Business (2018-2023)
11.5.5 Abbott Recent Development
11.6 Ionis Pharmaceuticals
11.6.1 Ionis Pharmaceuticals Company Detail
11.6.2 Ionis Pharmaceuticals Business Overview
11.6.3 Ionis Pharmaceuticals Prion Disease Drug Introduction
11.6.4 Ionis Pharmaceuticals Revenue in Prion Disease Drug Business (2018-2023)
11.6.5 Ionis Pharmaceuticals Recent Development
11.7 Lannett
11.7.1 Lannett Company Detail
11.7.2 Lannett Business Overview
11.7.3 Lannett Prion Disease Drug Introduction
11.7.4 Lannett Revenue in Prion Disease Drug Business (2018-2023)
11.7.5 Lannett Recent Development
11.8 Astellas Pharma Inc.
11.8.1 Astellas Pharma Inc. Company Detail
11.8.2 Astellas Pharma Inc. Business Overview
11.8.3 Astellas Pharma Inc. Prion Disease Drug Introduction
11.8.4 Astellas Pharma Inc. Revenue in Prion Disease Drug Business (2018-2023)
11.8.5 Astellas Pharma Inc. Recent Development
11.9 Sawai Pharmaceutical
11.9.1 Sawai Pharmaceutical Company Detail
11.9.2 Sawai Pharmaceutical Business Overview
11.9.3 Sawai Pharmaceutical Prion Disease Drug Introduction
11.9.4 Sawai Pharmaceutical Revenue in Prion Disease Drug Business (2018-2023)
11.9.5 Sawai Pharmaceutical Recent Development
11.10 Elite Pharmaceuticals, Inc.
11.10.1 Elite Pharmaceuticals, Inc. Company Detail
11.10.2 Elite Pharmaceuticals, Inc. Business Overview
11.10.3 Elite Pharmaceuticals, Inc. Prion Disease Drug Introduction
11.10.4 Elite Pharmaceuticals, Inc. Revenue in Prion Disease Drug Business (2018-2023)
11.10.5 Elite Pharmaceuticals, Inc. Recent Development
11.11 Teva Pharmaceuticals
11.11.1 Teva Pharmaceuticals Company Detail
11.11.2 Teva Pharmaceuticals Business Overview
11.11.3 Teva Pharmaceuticals Prion Disease Drug Introduction
11.11.4 Teva Pharmaceuticals Revenue in Prion Disease Drug Business (2018-2023)
11.11.5 Teva Pharmaceuticals Recent Development
11.12 Bristol Myers Squibb
11.12.1 Bristol Myers Squibb Company Detail
11.12.2 Bristol Myers Squibb Business Overview
11.12.3 Bristol Myers Squibb Prion Disease Drug Introduction
11.12.4 Bristol Myers Squibb Revenue in Prion Disease Drug Business (2018-2023)
11.12.5 Bristol Myers Squibb Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock